Factor IX deficiency treatment market scenario

Technavio’s market research analyst predicts the global factor IX deficiency treatment market to grow steadily at a CAGR of around 5% by 2021. One of the primary drivers for this market is the rapid shifting toward half-life drugs. The introduction of half-life drugs is a significant improvement in the field of hemophilia B. Less frequent dosing means potentially fewer infusion reactions and lesser opportunities to produce inhibitors, which ultimately leads to increased patient adherence. For instance, in 2014, Shire introduced RIXUBIS, which has an ability to achieve hemostatic efficacy for the prevention and treatment of bleeding in individuals with hemophilia B and during surgeries. These new launches and the ongoing extensive R&D for further product launches should continue fueling the market growth during the forecast period.

Get A Free Sample

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The hemophilia drugs market in the Americas is growing at a moderate pace owing to the presence of a high patient base in this region. The Americas contribute the highest revenue share in the global hemophilia market. Moreover, the health reforms have played crucial roles, which showed a positive impact on the market growth. For instance, in the US, the implementation of the ACA is rapidly changing the business environment for pharmaceuticals. Healthcare reforms in the US help in reducing the cost of pharmaceutical drugs, offer increased access to healthcare and improve the quality of healthcare.

Factor IX deficiency treatment market supply: Competitive landscape and key vendors

The global factor IX deficiency treatment market is highly consolidated with key vendors holding major market shares. In addition to the extensive ongoing R&D efforts, the vendors are also seeking to pursue inorganic growth strategies to leverage R&D expertise, technology platforms, or manufacturing strength of other companies.

Leading vendors in the market are

• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

Segmentation by disease type and analysis of the factor IX deficiency treatment market

• Hemophilia B
• Hemophilia B inhibitors

The global hemophilia B drugs market is expected to grow at a moderate pace during the forecast period. The growing incidence of hemophilia B is expected to drive the market growth. Also, the increasing demand for novel recombinant extended half-life products coupled with the emergence of monoclonal antibodies and gene therapy products will propel the growth of this segment in the next four years.

Segmentation by type of disease management and analysis of the factor IX deficiency treatment market

• Inhibitor therapy
• Prophylaxis
• On-demand therapy

In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market during the forecast period. Factors such a low cost and high efficiency are the key contributors to the dominance of this segment in the global market.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global factor IX deficiency treatment market?
• What are the key market trends impacting the growth of the global factor IX deficiency treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global factor IX deficiency treatment market?
• What are the market opportunities and threats faced by the vendors in the global factor IX deficiency treatment market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global factor IX deficiency treatment market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Anticoagulant Market 2017-2021 
• Global Antifungal Drugs Market 2017-2021 
• Global Atopic Dermatitis Drugs Market 2017-2021